Dreman Value Management’s United Therapeutics UTHR Stock Holding History

Dreman Value Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$389K	Hold	3,466	–	–	0.18%	158
2017 Q4	$513K	Hold	3,466	–	–	0.29%	100
2017 Q3	$406K	Hold	3,466	–	–	0.22%	147
2017 Q2	$450K	Buy	+3,466	New	+$432K	0.25%	112
2017 Q1	–	Sell	-146	Closed	-$21K	–	377
2016 Q4	$21K	Sell	146 -2,524	-95%	-$322K	0.01%	288
2016 Q3	$315K	Hold	2,670	–	–	0.19%	131
2016 Q2	$283K	Buy	2,670 +2,545	+2,036%	+$284K	0.18%	141
2016 Q1	$14K	Buy	+125	New	+$15.8K	﹤0.01%	394

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Dreman Value Management's UTHR Position: Q1 2018 in Review

Dreman Value Management held its United Therapeutics (UTHR) position steady in Q1 2018 at 3,466 shares worth $389K. The position accounts for 0.18% of the portfolio, ranked #158.

Dreman Value Management first reported a position in UTHR in Q1 2016 and has held it in 8 quarters since. The position peaked at $513K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

Dreman Value Management held 3,466 shares of United Therapeutics worth $389K as of Q1 2018.
Dreman Value Management left its United Therapeutics share count unchanged in Q1 2018.
United Therapeutics made up 0.18% of Dreman Value Management's portfolio in Q1 2018, its #158 holding.
Dreman Value Management first reported a position in United Therapeutics in Q1 2016 and has held it in 8 quarters since.
Dreman Value Management's United Therapeutics position peaked at $513K in Q4 2017.
374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Dreman Value Management's 13F filing for Q1 2018, filed 2 May 2018.